Merlin is a newly public autonomous-flight software company whose equity now prices a residual claim on a certification story rather than a scaled defense franchise. The March combination with Inflection Point Acquisition Corp. IV listed Merlin Labs under this ticker and left the operating company with a cash pile and no funded bank debt. What changed over the summer is not the arrival of product revenue. It is a cluster of program and regulator gates that management treats as commercialization itself. The special-operations Hercules contract cleared its formal design-review gate in early June. Civil software verification reached Stage of Involvement Three with New Zealand's aviation authority in early August. Those events matter because they convert a slide-deck autonomy claim into a documented path toward installation and a supplemental type certificate. The market still treats the equity as a post-listing leftover.
The tension is that the same quarter that produced those gates also showed how little of the $105 million indefinite-delivery ceiling has turned into billings. Second-quarter revenue was $2.2 million. Almost all of it came from tapped United States government task orders rather than a license on an operational fleet. Cash, cash equivalents, and short-term investments ended the period at $183.9 million after a May private placement. Operating cash outflow in the quarter was $27.3 million. Common stockholders sit junior to $162.5 million of redeemable Series A preferred and face a $130.1 million warrant liability that marks through earnings. The May raise also triggered a down-round deemed dividend that stripped another $60.8 million from the common residual on paper. Progress on the stack and damage to the common claim are arriving together.
The second-quarter print therefore answers a different question than the one the listing narrative advertised. Sequential revenue doubled from the first quarter, yet it still declined from the year-ago period, and adjusted earnings before interest, taxes, depreciation, and amortization were a $27.8 million loss. Research and development plus overhead now run far ahead of any contract-funded recovery. The investment debate is whether the next integration phase on the Hercules, the last software stage with New Zealand, and a conversion of cargo memoranda into paid work arrive while the cash still covers the burn. Does a certifiable portable brain become a license book, or does the preferred-and-warrant stack recapitalize the common first?